ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Glepaglutide (Zeydovio)

Zeydovio is indicated for the treatment of adults with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.

CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Zealand Pharma A/S

Research

Gastroenterology · Nutr Clin Pract · 2026-03-12

Secondary analysis (exit interviews) of a phase 3 trial in 30 patients with short bowel syndrome with intestinal failure: 73% (16/22) on glepaglutide vs 25% (2/8) on placebo reported better health-related quality of life; descriptive, small numbers.

Secondary analysisn = 30
Mercer et al. Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.